Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses

Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered.

[1]  T. Pawlik,et al.  Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma , 2018, Journal of surgical oncology.

[2]  T. Pawlik,et al.  Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients , 2018, Journal of cachexia, sarcopenia and muscle.

[3]  J. Backman,et al.  Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle , 2017, Journal of cachexia, sarcopenia and muscle.

[4]  C. Jacobi,et al.  Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy , 2017, Proceedings of the National Academy of Sciences.

[5]  S. Anker,et al.  Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017 , 2017, Journal of cachexia, sarcopenia and muscle.

[6]  J. Praestgaard,et al.  Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof‐of‐Concept Study , 2017, Journal of the American Geriatrics Society.

[7]  A. van Maanen,et al.  Circulating Activin A predicts survival in cancer patients , 2017, Journal of cachexia, sarcopenia and muscle.

[8]  E. Mervaala,et al.  Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes , 2016, Scientific Reports.

[9]  M. Watt,et al.  Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. , 2016, Cancer research.

[10]  L. V. van Loon,et al.  Is Cancer Cachexia Attributed to Impairments in Basal or Postprandial Muscle Protein Metabolism? , 2016, Nutrients.

[11]  S. Hatakeyama,et al.  ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments , 2016, Skeletal Muscle.

[12]  S. Hatakeyama,et al.  ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments , 2016, Skeletal Muscle.

[13]  Heather K. Neilson,et al.  Physical Activity and Cancer Outcomes: A Precision Medicine Approach , 2016, Clinical Cancer Research.

[14]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[15]  V. Baracos,et al.  Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. , 2016, Seminars in cell & developmental biology.

[16]  A. Fournier,et al.  Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. , 2016, JAMA internal medicine.

[17]  D. Guttridge,et al.  Impaired regeneration: A role for the muscle microenvironment in cancer cachexia. , 2016, Seminars in cell & developmental biology.

[18]  F. López‐Soriano,et al.  Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β‐2 agonist , 2016, International journal of cancer.

[19]  W. Berger,et al.  High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma , 2016, Oncotarget.

[20]  K. Murphy.  The pathogenesis and treatment of cardiac atrophy in cancer cachexia. , 2016, American journal of physiology. Heart and circulatory physiology.

[21]  T. Burkholder,et al.  Decrease of myofiber branching via muscle-specific expression of the olfactory receptor mOR23 in dystrophic muscle leads to protection against mechanical stress , 2015, Skeletal Muscle.

[22]  A. Vigano,et al.  MAP3K11/GDF15 axis is a critical driver of cancer cachexia , 2015, Journal of cachexia, sarcopenia and muscle.

[23]  S. Kulp,et al.  Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. , 2015, Journal of the National Cancer Institute.

[24]  F. López‐Soriano,et al.  Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations , 2015, Oncotarget.

[25]  A. Scott,et al.  Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival , 2015, Cell.

[26]  P. Hoen,et al.  Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice , 2015, Molecular and Cellular Endocrinology.

[27]  F. López‐Soriano,et al.  Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3 , 2014, PloS one.

[28]  T. Rantalainen,et al.  Validation of a method to measure total spontaneous physical activity of sedentary and voluntary running mice , 2014, Journal of Neuroscience Methods.

[29]  S. Rivella,et al.  Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. , 2014, Blood.

[30]  L. Moldawer,et al.  Novel Role for Tumor-Induced Expansion of Myeloid-Derived Cells in Cancer Cachexia , 2014, The Journal of Immunology.

[31]  T. Hornberger,et al.  The mechanical activation of mTOR signaling: an emerging role for late endosome/lysosomal targeting , 2014, Journal of Muscle Research and Cell Motility.

[32]  F. López‐Soriano,et al.  Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models , 2013, Journal of Lipid Research.

[33]  Q. Hu,et al.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. , 2013, The Journal of clinical investigation.

[34]  Stefano Piccolo,et al.  BMP signaling controls muscle mass , 2013, Nature Genetics.

[35]  W. Hoogaars,et al.  Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice. , 2013, American journal of physiology. Endocrinology and metabolism.

[36]  Adam W. Beharry,et al.  Diaphragm and ventilatory dysfunction during cancer cachexia , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Connie M. Rhee,et al.  Why cachexia kills: examining the causality of poor outcomes in wasting conditions , 2013, Journal of cachexia, sarcopenia and muscle.

[38]  Ravi Kumar,et al.  A single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers , 2013, Muscle & nerve.

[39]  V. Baracos,et al.  Understanding the mechanisms and treatment options in cancer cachexia , 2013, Nature Reviews Clinical Oncology.

[40]  W. Hoogaars,et al.  Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. , 2013, American journal of physiology. Endocrinology and metabolism.

[41]  G. Lynch,et al.  Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia , 2012, Disease Models & Mechanisms.

[42]  S. Werner,et al.  Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response , 2011, Nature communications.

[43]  G. Lesinski,et al.  Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. , 2011, Cancer research.

[44]  T. Zimmers,et al.  STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia , 2011, PloS one.

[45]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[46]  Philippe Pierre,et al.  Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  D. Glass,et al.  Treating cancer cachexia to treat cancer , 2011, Skeletal Muscle.

[48]  D. Lacey,et al.  Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival , 2010, Cell.

[49]  D. Sabatini,et al.  Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids , 2010, Cell.

[50]  T. Zimmers,et al.  Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. , 2010, Biochemical and biophysical research communications.

[51]  A. Baldi,et al.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse , 2010, BMC Cancer.

[52]  C. Cray,et al.  Acute phase response in animals: a review. , 2009, Comparative medicine.

[53]  M. Tisdale.  Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[54]  J. Argilés,et al.  Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice , 2009, British Journal of Cancer.

[55]  Philippe Pierre,et al.  SUnSET, a nonradioactive method to monitor protein synthesis , 2009, Nature Methods.

[56]  J. Argilés,et al.  Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice , 2009, British Journal of Cancer.

[57]  N. Stephens,et al.  Cachexia, survival and the acute phase response , 2008, Current opinion in supportive and palliative care.

[58]  M. Muscaritoli,et al.  Muscle myostatin signalling is enhanced in experimental cancer cachexia , 2008, European journal of clinical investigation.

[59]  M. Matzuk,et al.  Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. , 2007, Molecular human reproduction.

[60]  R. Wolfe.  The underappreciated role of muscle in health and disease. , 2006, The American journal of clinical nutrition.

[61]  J. Madelmont,et al.  Liver protein synthesis stays elevated after chemotherapy in tumour-bearing mice. , 2006, Cancer letters.

[62]  M. Matzuk,et al.  Regulation of muscle growth by multiple ligands signaling through activin type II receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. le Gall,et al.  The Prognosis of Acute Respiratory Failure in Critically Ill Cancer Patients , 2004, Medicine.

[64]  W. Frontera,et al.  IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.

[65]  Sylvain V Costes,et al.  Automatic and quantitative measurement of protein-protein colocalization in live cells. , 2004, Biophysical journal.

[66]  W. Frontera,et al.  IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. , 2004, Cell.

[67]  D. McMillan,et al.  Liver export protein synthetic rates are increased by oral meal feeding in weight-losing cancer patients. , 1998, American journal of physiology. Endocrinology and metabolism.

[68]  F. López‐Soriano,et al.  The role of cytokines in cancer cachexia , 1999, Medicinal research reviews.

[69]  F. Santolaria,et al.  Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. , 1999, Cytokine.

[70]  M. Tisdale,et al.  Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. , 1993, British Journal of Cancer.

[71]  J. Studnicki,et al.  Intensive care, survival, and expense of treating critically ill cancer patients. , 1993, JAMA.

[72]  F. Schabel,et al.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.